We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

41 hedge funds and large institutions have $1.1M invested in VYNE Therapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 41 → 41 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

0.09% less ownership

Funds ownership: 0.79% → 0.7% (-0.09%)

40% less capital invested

Capital invested by funds: $1.84M → $1.1M (-$738K)

67% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 15

Holders
41
Holders Change
–
Holders Change %
0%
% of All Funds
0.66%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
15
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$64.2K
2
UBS Group
UBS Group
Switzerland
+$9.82K
3
TSS
Two Sigma Securities
New York
+$4.2K
4
SG
StoneX Group
New York
+$3.07K
5
TFA
Tobias Financial Advisors
Florida
+$2.44K

Top Sellers

Rank Fund Capital Flow
1
DA
DSC Advisors
Illinois
-$244K
2
VF
Virtu Financial
New York
-$14K
3
Renaissance Technologies
Renaissance Technologies
New York
-$13.8K
4
Citadel Advisors
Citadel Advisors
Florida
-$7.25K
5
Jane Street
Jane Street
New York
-$7.14K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$248K +$248 +62 +0.1%
DA
2
DSC Advisors
Illinois
$236K -$244K -61,111 -41%
BlackRock
3
BlackRock
New York
$133K -$328 -82 -0.2%
Renaissance Technologies
4
Renaissance Technologies
New York
$130K -$13.8K -3,454 -7%
Millennium Management
5
Millennium Management
New York
$73K +$64.2K +16,072 +146%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$67K -$248 -62 -0.2%
State Street
7
State Street
Massachusetts
$31.5K – – –
TCM
8
Tekla Capital Management
Massachusetts
$20.3K – – –
Mackenzie Financial
9
Mackenzie Financial
Ontario, Canada
$20.2K – – –
CAN
10
Cetera Advisor Networks
California
$17.3K – – –
Franklin Resources
11
Franklin Resources
California
$14.4K – – –
Northern Trust
12
Northern Trust
Illinois
$13.4K – – –
Bank of America
13
Bank of America
North Carolina
$13.3K +$28 +7 +0.1%
BPA
14
Beacon Pointe Advisors
California
$11.1K -$224 -56 -1%
SCA
15
STALEY CAPITAL ADVISERS
Pennsylvania
$9K – – –
UBS Group
16
UBS Group
Switzerland
$8.2K +$9.82K +2,456 +423%
Citadel Advisors
17
Citadel Advisors
Florida
$8.09K -$7.25K -1,815 -38%
Thrivent Financial for Lutherans
18
Thrivent Financial for Lutherans
Minnesota
$8K – – –
DAM
19
Deltec Asset Management
New York
$4.5K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$4K -$328 -82 -5%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$3.99K – – –
CL
22
CSS LLC
Illinois
$3.62K – – –
Morgan Stanley
23
Morgan Stanley
New York
$3.5K -$68 -17 -1%
TSS
24
Two Sigma Securities
New York
$2.83K +$4.2K +1,050 New
MLA
25
MB, Levis & Associates
Pennsylvania
$2.81K +$4.17K +1,042 New
1
2

VYNE Hedge Fund Activity: Q4 2022 in Review

41 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2022, worth a combined $1.1M — down 40% from $1.84M a quarter earlier.

Fund positioning in VYNE was balanced in Q4 2022: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 15 trimmed.

The largest buyer was Millennium Management, adding an estimated $64.2K. The largest seller was DSC Advisors, cutting an estimated $244K.

  • 41 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $1.1M of VYNE Therapeutics stock for Q4 2022, down 40% quarter-over-quarter.
  • 4 funds opened new VYNE Therapeutics positions in Q4 2022 and 4 closed out, a net change of 0 holders.
  • The largest VYNE Therapeutics buyer in Q4 2022 was Millennium Management, an estimated $64.2K added.
  • The largest VYNE Therapeutics seller in Q4 2022 was DSC Advisors, an estimated $244K sold.

Based on aggregated 13F filings for Q4 2022.